|
Malcolm Berry "There are gaps in how industry and regulators think PAT should be used. One size does not fit all." |
|---|---|
|
Hans-Jürgen Federsel "What is the business case for applying flow chemistry/processing in the fine chemicals/pharmaceuticals area? Drivers and blockers for a swift transition to the novel production paradigm offered by flow processing on commercial scale?" |
|
Martijn de Graaff "The challenge for flexible plants is not in technology. It is in finding new ways to do business and earn money using this technology." |
|
Sebastian Härtner "How can we downsize well developed down streaming equipment for specialty chemistry in flow and introduce a modular concept for a wide range of parameters!" |
|
Johan ter Harmsel "Modularized Continuous Manufacturing Concepts have a high potential. But is it disruptive enough to change the entire Chemical Industry or will it be a novelty for niche markets only?" |
|
Norbert Kockmann "Downstream process units need robust and versatile equipment. Solids handling is a crucial issue in current process development. Chemists and engineers of various disciplines must work together." |
|
Patrick Löb "The combination of microreaction technology with a standardized chemical plant infrastructure is an ideal match to attain flexible, fast and mobile production. Further, additional potential lies in an integrated approach for process automatization form lab to pilot and production scale." |
|
Stefan Lier "There are still many challenges which have to be tackled before new production concepts are implemented in an operational environment in many places. Firstly, we need a development of modular apparatuses especially within separation technologies, secondly, logistics and operation concepts have to be adjusted and, thirdly, automation technologies and assistant systems have to support plug and produce concepts." |
|
Andreas Müller "Long research periods will throttle a new market introduction campaign and negatively impact later market penetration. We will need new strategies for speeding R&D campaigns on an increasingly competitive market. Research represents only one first step in product commercialization. Here also a proper research migration strategy, which considers later production aspects as well, will be essential. A high level of automation in R&D will not always guarantee best usage of invests, a proper automation migration strategy helps to adapt investments to a reasonable level." |
|
Peter Pöchlauer "We need considerable improvements in pharmaceutical manufacturing to ensure our supply with affordable high-quality medicines." |
|
Dirk Schmalz Joint stetement with Frank Stenger, Evonik: |
|
Armin Schweiger |
|
Frank Stenger Joint statement with Dirk Schmalz, Merck KGaA: |
|
Global Account Manager, Siemens AG, Germany "The Pharmaceutical and Chemical process Industries are challenged with market dynamics that require increased flexibility, faster market readiness and improved productivity, all under the highest quality conditions assuring patient safety. By introducing digitalization, one can achieve Integrated Engineering and Integrated Operations, which will able the industry to respond more agile to their customer requirements by an increase of in speed (time to market), flexibility and efficiency." |
|
Mathias Vornefeld |
|
Charlotte Wiles "What methods are people using to quantify the commercial benefits of continuous flow technology? What is considered to be a reasonable timeframe for ROI for a new technology?" |
|
The Moderator: Alexis Bazzanella |